Molecular You recently closed a round of financing, the Vancouver based preventative health startup announced, following “key achievements” this year.
The B.C.-based health tech innovator unveiled this month that it has secured US$5 million in financing.
The Series A round was led by Voloridge Health, according to a statement from Molecular You, and included participation from Dynamic Leap and others.
The company’s flagship product claims to measure more than 250 biomarkers across major systems with just a single blood sample.
The result is a deep, AI-powered analysis of health risks throughout 25 different “health areas,” according to the company, which includes personalized and actionable lifestyle recommendations to maximize preventative health.
Moving forward, Molecular You intends to apply the new capital to grow customers and expand the capabilities of the company’s technology, says Jim Kean, who became chief executive officer of the upstart in 2023.
“We plan to use this capital to grow our customer base across both consumer and clinical channels in North America, while also continuing to expand the platform’s analysis and predictive capabilities,” stated Kean.
The Series A round follows a nationwide launch of a direct-to-consumer online channel, a partnership with the HealthQuest Esoterics laboratory, and progress on the firm’s next-generation technology, which could measure up to 800 biomarkers for a higher resolution health analysis.
“Fragmented measurement of individual biomarkers cannot offer the same predictive capabilities as our platform, which sees the body as a whole,” explains Dr. Murdoc Khaleghi, Chief Medical Officer at Molecular You. “This is critical for predictive and preventative medicine, particularly for complex conditions like Alzheimer’s, PCOS, and autoimmune diseases, which are correlated to multiple individual biomarkers that are typically measured separately.”
David Vogel, CEO of Voloridge Health, believes that Molecular You “is advancing a critical shift in healthcare, from reactive treatment to predictive and preventive care, through biomarker science and real-world clinical impact.”
“Their unique multi-omic platform integrates proteomics and metabolomics in a way that sets a new standard for precision health,” he continued. “We believe Molecular You is well-positioned to transform how individuals and providers detect and manage disease risk at scale.”
Leave a Reply